Neuroprotective effect of cytoflavin in the treatment of premature newborns with hypoxic-ischemic encephalopathy

Objective. Evaluation of the effectiveness of Cytoflavin as a neuroprotective therapy for neurological complications in premature newborns with hypoxic-ischemic encephalopathy. Material and methods. 56 premature newborns with low body weight were examined. Newborn children, depending on the therapy, were divided into 2 groups: Group I — 32 premature newborns with hypoxic-ischemic encephalopathy; received basic therapy and Cytoflavin; Group II — 24 premature newborns with hypoxic-ischemic encephalopathy; received only basic therapy. Moreover, the state of neurospecific enolase (NSE) and blood lactate were studied. Results. Patients of the first group who received cytoflavin, on days 5—6 after treatment there was a decrease in the severity of cerebral ischemia. Also, decreased levels of NSE and blood lactate. Conclusion. The revealed neuroprotective effect of cytoflavin in the treatment of premature newborns with hypoxic-ischemic encephalopathy, good tolerability of the drug and its compatibility with other drugs used in the standard treatment of perinatal lesions of the nervous system, which makes it possible to recommend Cytoflavin for the treatment of neurometabolic disorders in children in the first months of life in complex therapy perinatal lesions of the nervous system of premature newborns.